Saving Lives: Early Lung Cancer Detection with CIZ1B Blood Test

A simple blood test for the detection of the CIZ1 B Biomarker in early-stage lung cancer.

The Challenge of Lung Cancer

Understanding the Urgency

At Cizzle Bio, Inc., we confront one of the most formidable challenges in healthcare today: the detection of lung cancer in its early stages. Lung cancer, the deadliest cancer worldwide, claims nearly 5,000 lives each day due to late-stage diagnoses. To illustrate the gravity of this issue, consider these crucial statistics:

The Statistics

Annual Diagnoses

Over 2.2 million individuals are diagnosed with lung cancer each year globally.

0

Mortality and Prevalence

In 2020, cancer claimed 10 million lives worldwide, with lung cancer accounting for nearly 20% of these fatalities - more than any other cancer.

Late-Stage Diagnosis

Approximately 75% of lung cancer cases are diagnosed at a late stage, drastically reducing survival rates and emphasizing the need for early detection.

Survival Rates

The survival rate for lung cancer increases dramatically when diagnosed early. However, less than 20% of cases are caught in these early stages.

Screening Rates

Only 5.8% of the eligible 14.2 million people have been screened for lung cancer as of 2021, pointing to a significant gap in preventive healthcare.

Current Screening Challenges

The traditional approach to lung cancer screening, primarily through CT scans, is fraught with difficulties. These scans have a high false positive rate of about 90%, leading to invasive, costly, and often unnecessary follow-up procedures. Despite the clear recommendations for lung cancer screening covering 14.2 million Americans, the actual uptake is alarmingly low, driven by socioeconomic barriers and limited access to necessary screening technology.

Our Response to the Challenge

In response to this pressing issue, Cizzle Bio has pioneered a simple yet profoundly effective solution: a blood test for the CIZ1B Biomarker. Demonstrated in early clinical studies to be highly associated with early-stage lung cancer, this biomarker test has shown a remarkable sensitivity of 95%. Protected by worldwide patents, our technology heralds a new era in cancer diagnostics, offering a non-invasive, cost-effective, and highly accurate alternative for early lung cancer detection.

Our Vision for the Future

Cizzle Bio is committed to bridging the significant gaps in lung cancer screening. By providing innovative diagnostic tools that facilitate early detection, we aim to dramatically reduce lung cancer mortality rates and save millions of lives. Join us as we advance lung cancer detection, transforming fear and uncertainty into hope and recovery.

Join us in the fight against lung cancer.

Help us change these dire statistics. Stay informed and support advancements in lung cancer diagnostics. Subscribe for updates. Enter your email addresses to receive news about the launch and developments.